86,610 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC acquired a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 86,610 shares of the company’s stock, valued at approximately $2,459,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in DYN. Walleye Capital LLC bought a new position in shares of Dyne Therapeutics in the third quarter worth about $2,511,000. Wellington Management Group LLP increased its position in shares of Dyne Therapeutics by 4.9% during the third quarter. Wellington Management Group LLP now owns 115,935 shares of the company’s stock worth $1,039,000 after acquiring an additional 5,371 shares during the period. Citigroup Inc. boosted its holdings in shares of Dyne Therapeutics by 22.8% in the third quarter. Citigroup Inc. now owns 61,895 shares of the company’s stock valued at $555,000 after purchasing an additional 11,508 shares during the period. SG Americas Securities LLC bought a new position in Dyne Therapeutics in the fourth quarter worth approximately $172,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Dyne Therapeutics by 355.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock worth $94,000 after purchasing an additional 5,541 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Price Performance

NASDAQ DYN traded down $0.42 during trading on Friday, hitting $41.54. The company’s stock had a trading volume of 790,563 shares, compared to its average volume of 1,105,983. Dyne Therapeutics, Inc. has a fifty-two week low of $6.40 and a fifty-two week high of $42.56. The company has a market cap of $3.63 billion, a PE ratio of -10.46 and a beta of 1.07. The business’s 50 day simple moving average is $32.30 and its 200-day simple moving average is $26.22.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, hitting analysts’ consensus estimates of ($0.81). Analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Susanna Gatti High sold 2,738 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $28.27, for a total value of $77,403.26. Following the transaction, the chief operating officer now owns 154,062 shares in the company, valued at approximately $4,355,332.74. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, insider Oxana Beskrovnaya sold 2,136 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $31.34, for a total transaction of $66,942.24. Following the completion of the transaction, the insider now directly owns 147,511 shares in the company, valued at $4,622,994.74. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Susanna Gatti High sold 2,738 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $28.27, for a total value of $77,403.26. Following the completion of the transaction, the chief operating officer now directly owns 154,062 shares of the company’s stock, valued at $4,355,332.74. The disclosure for this sale can be found here. Insiders sold 202,133 shares of company stock worth $6,500,387 in the last 90 days. Insiders own 20.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their price target on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research report on Tuesday. Chardan Capital raised their target price on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, May 21st. HC Wainwright increased their price objective on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, May 20th. Jefferies Financial Group lifted their price objective on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a report on Monday, May 20th. Finally, Oppenheimer restated an “outperform” rating and set a $47.00 target price on shares of Dyne Therapeutics in a report on Monday, May 6th. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.11.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.